Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.

[1]  G. Kaplan,et al.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. , 2008, The Journal of infectious diseases.

[2]  M. Horwitz,et al.  A Replication-Limited Recombinant Mycobacterium bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious than BCG , 2008, Infection and Immunity.

[3]  Bing Chen,et al.  Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. , 2007, The Journal of clinical investigation.

[4]  T. van der Poll,et al.  Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon , 2007, Infection and Immunity.

[5]  Julian Parkhill,et al.  Genome plasticity of BCG and impact on vaccine efficacy , 2007, Proceedings of the National Academy of Sciences.

[6]  H. Cai,et al.  A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. , 2006, DNA and cell biology.

[7]  Z. Xing,et al.  Intranasal Boosting with an Adenovirus-Vectored Vaccine Markedly Enhances Protection by Parenteral Mycobacterium bovis BCG Immunization against Pulmonary Tuberculosis , 2006, Infection and Immunity.

[8]  J. Sadoff,et al.  Advances in tuberculosis vaccine strategies , 2006, Nature Reviews Microbiology.

[9]  V. Chadha.  Tuberculosis epidemiology in India: a review. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  S. Kaufmann,et al.  Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. , 2005, The Journal of clinical investigation.

[11]  M. Aziz,et al.  The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Horwitz,et al.  Enhancing the Protective Efficacy of Mycobacterium bovis BCG Vaccination against Tuberculosis by Boosting with the Mycobacterium tuberculosis Major Secretory Protein , 2005, Infection and Immunity.

[13]  P. Andersen,et al.  The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.

[14]  A. Harries,et al.  Tuberculosis and HIV interaction in sub‐Saharan Africa: impact on patients and programmes; implications for policies , 2005, Tropical medicine & international health : TM & IH.

[15]  S. Reed,et al.  Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. , 2005, Vaccine.

[16]  Christopher Dye,et al.  Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. , 2005, JAMA.

[17]  D. Maher,et al.  Global epidemiology of tuberculosis. , 2005, Clinics in chest medicine.

[18]  M. Brennan,et al.  New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. , 2005, Vaccine.

[19]  A. Stryhn,et al.  Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy 1 , 2005, The Journal of Immunology.

[20]  C. Chintu,et al.  Tuberculosis in children with human immunodeficiency virus infection. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  R. Boyton.  Infectious lung complications in patients with HIV/AIDS , 2005, Current opinion in pulmonary medicine.

[22]  A. Thomas,et al.  Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. , 2005, Vaccine.

[23]  P. De Baetselier,et al.  The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen‐associated host innate immune responses , 2005, European journal of immunology.

[24]  H. McShane,et al.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans , 2004, Nature Medicine.

[25]  R. Al-Attiyah,et al.  In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis , 2004, Clinical and experimental immunology.

[26]  Ann Williams,et al.  Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model , 2004, Infection and Immunity.

[27]  P. Snoy,et al.  Immunization with a DNA Vaccine Cocktail Protects Mice Lacking CD4 Cells against an Aerogenic Infection with Mycobacterium tuberculosis , 2004, Infection and Immunity.

[28]  D. Wendling,et al.  The use of TNF-α blocking agents in rheumatoid arthritis: an overview , 2004, Expert opinion on pharmacotherapy.

[29]  D. McMurray,et al.  Coordinate Cytokine Gene Expression In Vivo following Induction of Tuberculous Pleurisy in Guinea Pigs , 2003, Infection and Immunity.

[30]  R. S. Sohal,et al.  Genotype and age influence the effect of caloric intake on mortality in mice , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[32]  R. North,et al.  Immunity to tuberculosis. , 2003, Annual review of immunology.

[33]  T. Ottenhoff,et al.  Epitope Mapping of the Immunodominant Antigen TB10.4 and the Two Homologous Proteins TB10.3 and TB12.9, Which Constitute a Subfamily of the esat-6 Gene Family , 2002, Infection and Immunity.

[34]  D. van Soolingen,et al.  Worldwide Occurrence of Beijing/W Strains of Mycobacterium tuberculosis: A Systematic Review , 2002, Emerging infectious diseases.

[35]  G. Delogu,et al.  DNA Vaccine Combinations Expressing Either Tissue Plasminogen Activator Signal Sequence Fusion Proteins or Ubiquitin-Conjugated Antigens Induce Sustained Protective Immunity in a Mouse Model of Pulmonary Tuberculosis , 2002, Infection and Immunity.

[36]  S. Kaufmann,et al.  How can immunology contribute to the control of tuberculosis? , 2001, Nature Reviews Immunology.

[37]  P. Andersen,et al.  Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6 , 2001, Infection and Immunity.

[38]  G. Kaplan,et al.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Horwitz,et al.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Dockrell,et al.  Human CD8+ T Cells Specific forMycobacterium tuberculosis Secreted Antigens in Tuberculosis Patients and Healthy BCG-Vaccinated Controls in The Gambia , 2000, Infection and Immunity.

[41]  J. Drijfhout,et al.  Identification of Major Epitopes of Mycobacterium tuberculosis AG85B That Are Recognized by HLA-A*0201-Restricted CD8+ T Cells in HLA-Transgenic Mice and Humans1 , 2000, The Journal of Immunology.

[42]  P. Andersen,et al.  Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells , 2000, European journal of immunology.

[43]  K. Lundin,et al.  Identification and HLA Restriction of Naturally Derived Th1-Cell Epitopes from the Secreted Mycobacterium tuberculosisAntigen 85B Recognized by Antigen-Specific Human CD4+T-Cell Lines , 2000, Infection and Immunity.

[44]  P. Andersen,et al.  Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT‐6 antigen , 2000, European journal of immunology.

[45]  P. Andersen,et al.  Comparative Evaluation of Low-Molecular-Mass Proteins fromMycobacterium tuberculosis Identifies Members of the ESAT-6 Family as Immunodominant T-Cell Antigens , 2000, Infection and Immunity.

[46]  S. Reed,et al.  Cloning, Expression, and Immunological Evaluation of Two Putative Secreted Serine Protease Antigens ofMycobacterium tuberculosis , 1999, Infection and Immunity.

[47]  S. Dorman,et al.  A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection , 1999, Nature Genetics.

[48]  P. Andersen,et al.  Two-Dimensional Electrophoresis for Analysis ofMycobacterium tuberculosis Culture Filtrate and Purification and Characterization of Six Novel Proteins , 1998, Infection and Immunity.

[49]  S. Kaufmann,et al.  Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Sterne,et al.  Does the efficacy of BCG decline with time since vaccination? , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[51]  J. Belisle,et al.  Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry , 1997, Infection and immunity.

[52]  M. Newport,et al.  Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. , 1996, The New England journal of medicine.

[53]  D. Portnoy,et al.  Conversion of an extracellular cytolysin into a phagosome‐specific lysin which supports the growth of an intracellular pathogen , 1996, Molecular microbiology.

[54]  C S Berkey,et al.  The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. , 1995, Pediatrics.

[55]  M. Horwitz,et al.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Andersen,et al.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins , 1994, Infection and immunity.

[57]  F. Mosteller,et al.  Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature , 1994 .

[58]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[59]  I. Orme,et al.  Disseminated tuberculosis in interferon gamma gene-disrupted mice , 1993, The Journal of experimental medicine.

[60]  J. Flynn,et al.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Horwitz,et al.  Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis , 1992, Infection and immunity.

[62]  P. Hopewell,et al.  Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  R K Tweten,et al.  Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells , 1992, Infection and immunity.

[64]  D. Snider,et al.  Tuberculosis in patients with human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[65]  H. McShane,et al.  Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. , 2005, Tuberculosis.

[66]  S. Laal,et al.  Immune-Based Methods , 2005 .

[67]  Stewart T. Cole,et al.  Tuberculosis and the tubercle bacillus. , 2005 .

[68]  D. Rock.  Tuberculosis: a global emergency. , 1997, Work.

[69]  M. Raviglione,et al.  Global tuberculosis incidence and mortality during 1990-2000. , 1994, Bulletin of the World Health Organization.

[70]  A. Kochi,et al.  Tuberculosis: a global overview of the situation today. , 1992, Bulletin of the World Health Organization.

[71]  A. Carroll,et al.  The SCID mouse mutant: definition, characterization, and potential uses. , 1991, Annual review of immunology.

[72]  L. Lugosi,et al.  Transformation of BCG with plasmid DNA. , 1989, Acta leprologica.